Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Schering-Plough overcomes “tough challenges”

Schering-Plough overcomes “tough challenges”

21st July 2009

Schering-Plough has announced its financial results for the second quarter of 2009, stating that it has been able to overcome “tough challenges” to report operational sales growth of four per cent.

In a statement, the company also reported a net income of $633 million (385 million pounds) over the three-month period.

Fred Hassan, chairman and chief executive of Schering-Plough, attributed the firm’s success to a “successful diversification strategy” and “strong execution” by the professionals who work at the business.

He added: “Our diverse product strength – from Remicade to Temodar to Nuvaring to Miralax – and our rich geographic diversity helped drive our operational growth.”

The company stressed the importance of research and development during the current climate, explaining that its strengths in this area, along with its “steady product flow”, are a “special asset” to Schering-Plough.

Earlier this month, the company announced positive results from a phase III trial for the follicle stimulant corifollitropin alfa.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.